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Background
Factor V Leiden mutation is a recognized most preva-
lent genetic risk factor for venous thromboembolic dis-
ease. Factor V mutations, are known to potentiate the
effect of MTHFR on deep vein thrombosis. The thermo
labile variant of the MTHFR gene (C677T) increases the
plasma homocysteine levels and hyperhomocysteneimia
is a known risk factor of deep vein thrombosis. Results
of studies concerning interaction of Hyperhomocystenei-
mia and thromobophilic risk factors like Factor V are
contradictory. Some studies have shown an increased
risk (10-50 times) of deep vein thrombosis because of
MTHFR and FVL mutations combined, yet other studies
fail to conclude similarly. We attempt to address this
paradox in our study referred for DVT, Hyperhomocyste-
neimia and pulmonary embolism and assess the impor-
tance of the synergistic effects of FVL and MTHFR
mutations.
Material and methods
In this study we analyzed 190 (79 females and 111 males)
cases referred to Kokilaben Dhirubhai Ambani Hospital
and Medical Research Institute (Jan 2009 to Aug 2013) for
DVT, Hyperhomocysteneimia and pulmonary embolism.
MTHFR mutation was studied in 27 of the above subset.
The detection of FVL mutation by PCR was studied by
Restriction Fragment length polymorphism and for
MTHFR (C677T & A1298C) mutations detection was
done using commercially available kit.
Results
FVL mutation was found to be present in 10% (19/190)
in our study population. Of these, 18 patients were het-
erozygous and 1 was homozygous for this mutation. Of
which 25% (19/76) patients with deep vein thrombosis
were positive for variants of FVL. 74% (20/27) of the
patients screened for MTHFR were found to be positive
(5 for C677T, 4 were compound heterozygous & 11 for
A1298C). 2 out of 4 patients who were positive for both
FVL and C677T MTHFR mutations had poor prognosis
and died.
Conclusions
Our study reconfirms the Synergistic role of factor V
Leiden and MTHFR (14.8%) in hypercoagulability disor-
ders like DVT, thromboembolism and others leading to
poorer prognosis.
Published: 21 January 2014
doi:10.1186/1755-8166-7-S1-P28
Cite this article as: Bansal: Factor V Leiden and MTHFR mutations as a
combined risk factor for hypercoagulability in referred Patients
population from Western India. Molecular Cytogenetics 2014 7(Suppl 1):
P28.
Correspondence: priya.b9@gmail.com
Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Four
Bungalows, Andheri West, Mumbai, India
Bansal Molecular Cytogenetics 2014, 7(Suppl 1):P28
http://www.molecularcytogenetics.org/content/7/S1/P28
© 2014 Bansal; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
